Cumberland Pharmaceuticals forms joint venture with RedHill to commercialize Talicia H. pylori therapy

CUMBERLAND PHARMACEUTICALS INC

Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.
RedHill contributes all Talicia assets; Cumberland handles distribution and records product sales.
Talicia generated $8M net revenue in 2024; both companies equally share net revenues.
Talicia is FDA-approved for H. pylori, patent protected through 2042, with QIDP exclusivity.
Product has broad insurance coverage: 70% commercial, 60% government; CVS stocks at 1,700 pharmacies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.